Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shionogi & Co., Ltd. (4507.T)
Osaka, JP
Shionogi & Co., Ltd., an Osaka, Japan-based pharmaceutical company established in 1878, focuses on the discovery, development, production, and commercialization of medicines, diagnostic tools, and medical devices primarily within Japan. The company, known as Shionogi Shoten Co., Ltd. until its rebranding in 1943, maintains a comprehensive portfolio. Its marketed products include Fetroja, an agent for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral treatment for influenza; and Tivicay, utilized in HIV therapy. Shionogi's extensive pipeline features investigational therapies such as Symproic for opioid-induced constipation; S-120083 for inflammatory pain and S-010887 for neuropathic pain; S-117957 for insomnia; sivopixant, addressing neuropathic pain, sleep apnea syndrome, and persistent chronic cough; S-637880 for neuropathic low back pain; Zuranolone for depression; SDT-001 for attention-deficit/hyperactivity disorder; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for obesity. Further development initiatives encompass ADR-001 for decompensated liver cirrhosis; S-723595 for NASH; various oncology candidates including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 for solid tumors, S-222611 for malignant tumors, and S-531011 for solid tumors; S-770108 for idiopathic pulmonary fibrosis; SR-0379 for cutaneous ulcers; S-005151 for stroke and epidermolysis bullosa; S-0373 for spinocerebellar ataxia; and multiple compounds targeting COVID-19, such as S-600918, S-217622, and S-555739 for mitigating disease progression. Additionally, the firm offers antibody test kits for COVID-19. Shionogi fosters strategic alliances, including collaborations with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University, aimed at advancing antimalarial drug research.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.62% | -5.34% | -12.16% | -16.24% | +10.12% | +3.35% | +31.45% | +44.44% | +52.03% | +50.76% | +614.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 9 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.0% ★ Q1'26: +32.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+20.4% ★ Q1'26: +28.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+27.6% Q1'26: +60.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+32.3% ★ Q1'26: +20.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.4% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.63× ★ Q1'26: 4.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 12 Rev. Ana. 12 EPS Ana. |
Mar 2027 1 Rev. Ana. 9 EPS Ana. |
Mar 2028 10 Rev. Ana. 11 EPS Ana. |
Mar 2029 5 Rev. Ana. 5 EPS Ana. |
Mar 2030 2 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
273.99B
est: 272.81B (+0.4%)
|
309.97B
est: 305.73B (+1.4%)
|
338.89B
est: 335.74B (+0.9%)
|
344.67B
est: 345.96B (-0.4%)
|
363.72B
est: 359.60B (+1.1%)
|
333.37B
est: 345.39B (-3.5%)
|
297.18B
est: 306.67B (-3.1%)
|
335.14B
est: 313.69B (+6.8%)
|
426.68B
est: 427.57B (-0.2%)
|
435.08B
est: 423.36B (+2.8%)
|
438.27B
est: 456.22B (-3.9%)
|
503.14B
487.87B – 517.90B
+10.3% YoY
|
683.63B
669.55B – 692.10B
+35.9% YoY
|
715.44B
685.95B – 733.20B
+4.7% YoY
|
728.60B
720.16B – 737.05B
+1.8% YoY
|
726.27B
711.32B – 735.27B
-0.3% YoY
|
714.53B
699.82B – 723.38B
-1.6% YoY
|
| EBITDA |
66.02B
est: 131.08B (-49.6%)
|
107.28B
est: 146.89B (-27.0%)
|
124.52B
est: 161.31B (-22.8%)
|
134.23B
est: 166.22B (-19.3%)
|
157.74B
est: 172.78B (-8.7%)
|
141.50B
est: 165.95B (-14.7%)
|
107.61B
est: 147.35B (-27.0%)
|
127.02B
est: 150.72B (-15.7%)
|
176.41B
est: 205.44B (-14.1%)
|
186.70B
est: 202.82B (-7.9%)
|
180.26B
est: 218.56B (-17.5%)
|
241.04B
233.73B – 248.11B
+10.3% YoY
|
327.51B
320.76B – 331.56B
+35.9% YoY
|
342.75B
328.62B – 351.26B
+4.7% YoY
|
349.06B
345.01B – 353.10B
+1.8% YoY
|
347.94B
340.77B – 352.25B
-0.3% YoY
|
342.31B
335.27B – 346.55B
-1.6% YoY
|
| EBIT |
50.37B
est: 118.63B (-57.5%)
|
91.41B
est: 132.94B (-31.2%)
|
108.18B
est: 145.99B (-25.9%)
|
115.22B
est: 150.43B (-23.4%)
|
138.54B
est: 156.36B (-11.4%)
|
127.38B
est: 150.18B (-15.2%)
|
92.83B
est: 133.35B (-30.4%)
|
110.67B
est: 136.40B (-18.9%)
|
159.25B
est: 185.92B (-14.3%)
|
168.38B
est: 184.76B (-8.9%)
|
159.32B
est: 199.10B (-20.0%)
|
219.58B
212.91B – 226.02B
+10.3% YoY
|
298.34B
292.20B – 302.04B
+35.9% YoY
|
312.23B
299.35B – 319.98B
+4.7% YoY
|
317.97B
314.28B – 321.66B
+1.8% YoY
|
316.95B
310.43B – 320.88B
-0.3% YoY
|
311.83B
305.41B – 315.69B
-1.6% YoY
|
| Net Income |
44.06B
est: 32.25B (+36.6%)
|
66.69B
est: 56.51B (+18.0%)
|
83.88B
est: 73.40B (+14.3%)
|
108.87B
est: 90.17B (+20.7%)
|
132.76B
est: 114.62B (+15.8%)
|
122.19B
est: 116.93B (+4.5%)
|
111.86B
est: 105.83B (+5.7%)
|
114.19B
est: 102.97B (+10.9%)
|
184.97B
est: 164.85B (+12.2%)
|
162.03B
est: 150.11B (+7.9%)
|
170.44B
est: 173.62B (-1.8%)
|
196.37B
180.73B – 207.45B
+13.1% YoY
|
222.15B
173.30B – 304.68B
+13.1% YoY
|
252.20B
189.51B – 303.05B
+13.5% YoY
|
253.06B
207.32B – 304.95B
+0.3% YoY
|
238.82B
232.42B – 242.66B
-5.6% YoY
|
171.04B
166.46B – 173.79B
-28.4% YoY
|
| SGA |
92.57B
est: 67.10B (+37.9%)
|
94.02B
est: 75.20B (+25.0%)
|
93.03B
est: 82.58B (+12.6%)
|
95.59B
est: 85.10B (+12.3%)
|
101.98B
est: 88.45B (+15.3%)
|
91.80B
est: 84.95B (+8.1%)
|
88.39B
est: 75.43B (+17.2%)
|
87.88B
est: 77.16B (+13.9%)
|
93.64B
est: 105.17B (-11.0%)
|
94.99B
est: 103.20B (-8.0%)
|
97.06B
est: 111.21B (-12.7%)
|
122.65B
118.93B – 126.25B
+10.3% YoY
|
166.65B
163.22B – 168.71B
+35.9% YoY
|
174.41B
167.21B – 178.73B
+4.7% YoY
|
177.61B
175.55B – 179.67B
+1.8% YoY
|
177.04B
173.40B – 179.24B
-0.3% YoY
|
174.18B
170.60B – 176.34B
-1.6% YoY
|
| EPS |
44.18
est: 37.90 (+16.6%)
|
68.21
est: 66.41 (+2.7%)
|
86.54
est: 86.26 (+0.3%)
|
114.12
est: 105.97 (+7.7%)
|
141.30
est: 134.70 (+4.9%)
|
131.77
est: 137.42 (-4.1%)
|
121.55
est: 124.37 (-2.3%)
|
126.12
est: 121.00 (+4.2%)
|
206.90
est: 193.73 (+6.8%)
|
186.17
est: 174.09 (+6.9%)
|
200.36
est: 205.13 (-2.3%)
|
230.24
212.39 – 243.79
+12.2% YoY
|
263.22
203.65 – 358.05
+14.3% YoY
|
292.79
222.71 – 356.14
+11.2% YoY
|
276.63
243.63 – 358.37
-5.5% YoY
|
280.65
273.14 – 285.17
+1.5% YoY
|
201.00
195.62 – 204.24
-28.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Isao Teshirogi | Chief Executive Officer, President & Representative Director | 269M | — |
| John Apeler Keller | Senior Executive Officer, SVice President of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director | — | — |
| Kazuhiro Hatanaka | Senior Executive Officer & Senior Vice President of Corporate Supervisory Unit | — | male |
| Masashi Deguchi | Corporate Officer & Senior Vice President of Sustainability Management Division | — | — |
| Takeshi Shiota | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div. | — | male |
| Takuji Fujiwara | Accounting & Finance Manager | — | — |
| Toshinobu Iwasaki | Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit | — | male |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office | — | — |
| Akira Kato | Senior Executive Officer and Senior Vice President of Supply Supervisory Unit | — | — |
| Yoshimasa Kyokawa | Vice President of Corporate Communications & Secretary Office | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4507.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
